Distribute iCAD TotalLook System for Growing Digital Mammography Market
iCAD’s TotalLook Product Supports Enhanced Comparative Review of Prior Film and Current Digital Mammograms When Converting to Digital Mammography
iCAD®, Inc. (Nasdaq: ICAD), an industryleading provider of Computer Aided Detection (CAD) solutions, and Siemens Medical Solutions, a world leader in medical imaging and information technology (IT) solutions, have announced that Siemens will offer iCAD’s TotalLook system as an option for use with its MAMMOMAT® NovationDR full-field digital mammography system, through Siemens global sales and distribution channels. TotalLook, introduced by iCAD at the end of 2005, provides customers with a comprehensive film-to-digital solution making it easier for women’s health centers to transition from film to digital mammography.
This new technology assists radiologists in comparing breast images year-to-year to detect subtle changes that may be indicative of breast cancer. Based on successful installations of iCAD systems with its customers, Siemens made the decision to offer the TotalLook system as an option for its digital mammography customers. Siemens also distributes iCAD’s Second Look Digital solution for computer aided detection of breast cancer.
TotalLook converts prior film images into a digital format for comparison with more recent images from digital mammography systems. It automatically adjusts the digitized images for correct display on Siemens’ MammoReportPlus softcopy reporting workstation. By providing radiologists with a “total look” at a patient’s multi-year mammograms, the solution helps detect subtle changes that may be indicative of breast cancer. In addition, it eliminates the need to shift back and forth from a light box to a digital workstation increasing workflow and improving productivity. The TotalLook solution has the capability to:
• Automatically retrieve and receive patient information from HL-7 or DICOM worklists • Digitize standard mammography films in 23 seconds • Capture the full fidelity of original film mammograms in each digitized image • Track and label records in industry-standard DICOM format • Send complete records to multiple DICOM destinations simultaneously • Display high-resolution digitized images on many DICOM workstations in any hanging protocol
About Siemens Medical Solutions
Siemens Medical Solutions of Siemens AG (NYSE: SI) with headquarters in Malvern, Pennsylvania, and Erlangen, Germany, is one of the largest suppliers to the healthcare industry in the world. The company is known for bringing together innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable, clinical and financial outcomes. Employing approximately 33,000 people worldwide and operating in more than 120 countries, Siemens Medical Solutions reported sales of 7.6 billion EUR, orders of 8.6 billion EUR and group profit of 976 million EUR for fiscal 2005.
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to identify cancer and other life-threatening conditions earlier by making medical services more effective, more accessible and more affordable for patients worldwide. Recipient of Frost & Sullivan’s Growth Strategy Leadership award, iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by over eleven hundred women’s healthcare centers worldwide.
„Safe Harbor“ Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forwardlooking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
iCAD and Second Look are registered trademarks of iCAD, Inc.
For iCAD investor relations, contact Kevin McGrath of Cameron Associates at +1 212-245-4577 or via email at kevin@cameronassoc.com. For Siemens public relations, contact Amanda Naiman at +1 610-448-4531 or via email at amanda.naiman@siemens.com.
Media Contact
Alle Nachrichten aus der Kategorie: Medizin Gesundheit
Dieser Fachbereich fasst die Vielzahl der medizinischen Fachrichtungen aus dem Bereich der Humanmedizin zusammen.
Unter anderem finden Sie hier Berichte aus den Teilbereichen: Anästhesiologie, Anatomie, Chirurgie, Humangenetik, Hygiene und Umweltmedizin, Innere Medizin, Neurologie, Pharmakologie, Physiologie, Urologie oder Zahnmedizin.
Neueste Beiträge
Sensoren für „Ladezustand“ biologischer Zellen
Ein Team um den Pflanzenbiotechnologen Prof. Dr. Markus Schwarzländer von der Universität Münster und den Biochemiker Prof. Dr. Bruce Morgan von der Universität des Saarlandes hat Biosensoren entwickelt, mit denen…
Organoide, Innovation und Hoffnung
Transformation der Therapie von Bauchspeicheldrüsenkrebs. Bauchspeicheldrüsenkrebs (Pankreaskarzinom) bleibt eine der schwierigsten Krebsarten, die es zu behandeln gilt, was weltweite Bemühungen zur Erforschung neuer therapeutischer Ansätze anspornt. Eine solche bahnbrechende Initiative…
Leuchtende Zellkerne geben Schlüsselgene preis
Bonner Forscher zeigen, wie Gene, die für Krankheiten relevant sind, leichter identifiziert werden können. Die Identifizierung von Genen, die an der Entstehung von Krankheiten beteiligt sind, ist eine der großen…